The unique benefits of proton therapy
Proton therapy is gaining traction as one of the most effective forms of radiation treatment, especially for patients with specific tumor types and locations. Dr. Johnstone highlights some of the key advantages:
- Higher dose delivery: Proton therapy allows for a higher dose to be delivered directly to the tumor, minimizing exposure to surrounding healthy tissues. This is particularly beneficial for delicate areas such as the brainstem and spinal region.1
- Less radiation to surrounding tissues: This treatment is vital for pediatric patients as it reduces the amount of radiation exposure to growing tissues, promoting better long-term health outcomes.1,2
- Retreatment capabilities: Proton therapy is also effective for patients requiring retreatment, especially in challenging spine and thorax cases.2
Discover IBA’s ProteusONE unequaled beam quality, designed to maximize proton therapy treatment possibilities and improve patient care, here.
Selecting the right proton therapy partner
When Moffitt Cancer Center sought a provider for proton therapy, the decision was not taken lightly. Dr. Johnstone explains that the selection process was thorough and rigorous, emphasizing not just current capabilities but also future clinical utility. After an extensive selection process, IBA emerged as the preferred partner. The choice of IBA was influenced by their commitment to innovation and their understanding of the evolving landscape of proton therapy.
Read more about IBA’s focus on new innovations and improvements for proton therapy centers here.
IBA’s ProteusONE advantages
Dr. Johnstone specifically highlighted the advantages of IBA's ProteusONE system. His previous experience with IBA gantries during his time in Indiana gave him confidence in their technology. The Moffitt Cancer Center chose IBA’s ProteusONE system not just because of its current state-of-the-art capabilities but because it embraces a forward-thinking approach to what will be possible in proton therapy. Given the 10-year contract between Moffitt and IBA, the partnership must continuously adapt and evolve with proton therapy technological advancements.
Discover IBA’s commitment to create the future of proton therapy innovations with DynamicARC* and ConformalFLASH*.
In conclusion, Moffitt Cancer Center's selection of IBA as a partner for proton therapy underscores the importance of choosing a provider that prioritizes both present and future advancements. The collaboration promises to lead to groundbreaking developments in treating complex tumors while ensuring that patient care remains at the forefront. This partnership is indeed a significant step towards improving outcomes for patients today and in the years to come.
References
- Mohan, R. et al. Proton therapy – Present and future. Adv Drug Deliv Rev. 2017;10926–44. DOI: 10.1016/j.addr.2016.11.006
- Yuan, T.Z. et al. New frontiers in proton therapy: Applications in cancers. Cancer Commun. 2019;39(1):. DOI: 10.1186/s40880-019-0407-3
Notes
Disclaimer: The statements of the healthcare professional included in this testimonial reflect only his opinion and personal experience. They do not necessarily reflect the opinion of any institution with whom he is affiliated or IBA.
* ConformalFLASH & DynamicARC are registered brands of IBA’s Proton Therapy which are currently under research and development. ConformalFLASH and DynamicARC will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.
